Summary. Tolbutamide and glibenelamide (glyburide) were administered to normal hamsters, mice or rats in daily doses proportional to their body weight and equivalent to those used in human therapy. The animals were sacrificed after 6 to 8 weeks of treatment. Pieces of pancreas or isolated pancreatic islets were incubated or perifused in a medium containing glucose or tolbutamide, with or without leueine-114C or glucose-U-14C. The results indicate that the B cells of sulfonylurea treated animals synthesized and released less insulin and oxidized less glucose than those of insulin or saline treated controls. Accordingly, at least in the glibenelamide treated animals, the tolerance for glucose and the insulinogenie response to a glucose load in vivo were suppressed. Although insular function tended to return.to normal after treatment was discontinued, the results reported in this paper do not support the generally aeeepted view that the lasting therapeutic effectiveness of the sulfonylureas is due to a beta-cytotrophie action.
Pancreatic-femoral cross circulation experiments between two dogs demonstrated that, when a sulfonylurea derivative was injected into one of the animals, the second animal, recipient of the pancreatic blood of the first, becomes hypoglycemic [1, 2] . This and other indirect evidence suggests that the sulfonylureas release insulin from the pancreas [3] , a notion confirmed by direct measurements of insulin in vivo and in vitro [4--7] and now generally accepted. Indeed, the rise in serum insulin levels observed following the intravenous injection of tolbutamide sodium is often used as an element in the clinical evaluation of insular function. The immediate result of this drug-induced insulin release is a depletion of the pancreatic islets, as indicated by functional [8, 9] and by morphologic [10, 11] evidence. Obviously, if this release were to continue indefinitely without adequate insulin resynthesis, the drugs would soon become ineffective and functional bankruptcy of the B cells would ensue. Clinical experience teaches that this is not the case, for no convineing or even suggestive evidence of lasting changes in insular function have been reported in man, even though countless diabetics have received oral medication for many years. In animals, however, the results of prolonged administration of sulfonylureas have been contradietory: islet hypertrophy, beta cell multiplication and increased tolerance for glucose [12, 13] , but also a decrease in islet activity or no change at all [4, 8, 14, 15] have been observed. Indeed, it has been suggested that the drugs, while stimulating the release of insulin, may fail to stimulate its replacement [7] . l~eeently we have reported that pancreatic islets, isolated from normal hamsters after prolonged treatment with tolhutamide, secreted significantly smaller amounts of insulin than islets of control animals [16] .
The purpose of the experiments reported here was to investigate further the effects of the sulfonylureas on the insulinogenic reserve of normal animals in vivo and on the secretory and metabolic activities of their pancreatic islets in vitro.
Material and Methods
Female Syrian hamsters (100 to 120 g) and female Swiss mice (20 to 25 g) were kept in individual cages and weighed once a week. Unless otherwise indicated, the animals were given a diet of Purina Rat Chow and water acl libitum.
In one series of experiments, hamsters received daily doses of tolbntamide (63 mg/kg, intraperitoneally) or of nltralente insulin (1.0 U/100 g, subcutaneously). Control animals were given i.p. or s.c. injections of 0.9% sodium chloride. After 6 to 8 weeks of treatment and 24 h after the last injection, the hamsters were sacrificed by cervical dislocation and their pancreata were removed, trimmed of visible fat and connective tissue and cut into small pieces. From these pieces, islets were isolated using the method of Lacy and Kostianovsky [17] and transferred to a millipore filter (diameter 13 ram; pore size 5.0 ~). The filter was placed in a millipore holder (Millipore Corporation, ]~edford, Mass.) that served as a perifusion chamber and KrebsRinger bicarbonate, containing bovine serum albumin (0.5 g/100 ml), was pushed through it at the rate of 0.8--1.0 ml/min with a peristaltic pump. The buffer was gassed continuously with a mixture of oxygen (.95%) and carbon dioxide (5%) and the pH was maintained between 7.35 and 7.45 throughout the experiment. Two ehambers, containing a control and an experimental sample, were perifused simultaneously, in parallel, while immersed in a water bath at 37~ The buffer reservoir was kept in the same bath. The effluents were collected in graduated test tubes, their volumes were noted and aliqnots were used for insulin assay, according to the method of Malaisse et al. [i8], using a porcine insulin standard.
For the first 50 min the islets were perifused with buffer containing glucose at a concentration of 50 mg/100 ml and samples of effluent were collected every 5 rain. After this period of equilibration one of the chambers was switched to a buffer containing glucose at a concentration 300 rag/100 ml, while the other continued to be perifused with the initial buffer. Thereafter, samples of effluent were collected every min for 20 min; then every 5 min for an additional 100 min.
In a second series of experiments, hamsters that had been treated with tolbutamide (63 mg/kg/day for 6 to 8 weeks) or with ultralente insulin (1.0 U/100 g/day for 8 weeks) and mice that had been treated with glibenclamide (2.0 mg/kg/day for 8 weeks) were killed 24 or 48 h after receiving the last dose of the respective drug. Pieces of pancreas were prepared as described above and 50 to 70 mg of pancreatic tissue (not of isolated islets) were placed in 25 ml Erlenmeyer flasks with 2 ml of Krebs-Ringer bicarbonate buffer, containing bovine serum albumin (1 g/100 ml), glucose (30 or 250 mg/100 ml), leucine-l-14C (28 me/raM, 0.5 ~c/ml), with or without tolbutamide sodium (20 rag/100 ml). The samples were equilibrated for 5 min with 03 (95~o) and CO s (5~o) and incubated for 2 h, in a Dubnoff metabolic shaker, under this gas mixture. After incubation, the pieces of tissue were removed and placed in I0~o triehloracetic acid. Insulin was extracted according to the method of Grodsky et al. [19] , and purified, using a modification of the double antibody techniques of Taylor et al. [20] and Howell et al. [2i], as follows: 1.0 ml of the crude insulin solution was incubated with 0.5 ml of guinea pig anti-insulin serum and 2.0 ml of rabbit anti-guinea pig gamma globulin and the floceulent precipitate was re-extracted with 1.0 ml of acid alcohol (ethanol : water: HC1 = 3 : 1 : 0.3; v/v/v). One aliquot of the extract was used for the determination of its insulin content, as stated above, the rest was mixed with Bray's scintillation fluid for the measurement of radioactivity. Pieces of liver were incubated and extracted under the same conditions and their radioactivity was subtracted from that of the pancreatic extracts. The specific activity (cpm/mU) of the insulin rich extract, corrected for the contribution of non-insulin impurities, was used as a measure of insulin synthesis.
In a third series of experiments, after 6 to 8 weeks of treatment with tolbutamide (63 mg/kg), with insulin (1.0 U/100 g) or with suitable volumes of saline, hamsters were sacrificed and their islets isolated as described above. Samples of 15 to 25 islets were placed in 15 ml Erlenmeyer flasks containing l ml of KrebsRinger bicarbonate buffer with bovine serum albumin (0.5 g/f00 ml), glucose (100 or 300 rag/100 ml) and glucose-U-14C (1.0 ~c/ml). After equilibration for 5 min with the O~-CO~ mixture, the flasks were closed with a rubber stopper, holding a smallplastie well, andincnbated for 3 h at 37 ~ C in a Dubnoff metabolic shaker. These experiments were terminated by injecting 0.2 ml of 10N H2SO 4 into the medium and 0.5 ml of hyamine hydroxide 10 • into the plastic well. After 1 h, the hyamine was transferred to a scintillation vial for measurement of radioactivity. Two flasks, containing medium and labelled glucose, but no islets, were carried through the entire procedure to provide background counts.
In a fourth series of experiments, female SpragueDawley rats, weighing 250 to 300 g were treated with single or with daily injections of tolbutamide (63 mg/ kg) or glibenclamide (i.2 mg/kg) for 8 weeks. Twentyfour and 48 h after the last injection, respectively, the rats were given an intravenous dose of glucose (1.0 g/ kg) or of tolbutamide (20 mg/kg) and blood samples were taken for glucose and insulin determinations at various intervals of time. Glucose was measured using an oxidase method adapted to the Auto Analyzer [22] ; insulin was measured as stated above.
The intervals of time between the last dose and the sacrifice of the animal were deemed sufficient to reduce the concentration of the drugs in the serum to pharmacologically insignificant levels, given a biologic half-life of 3.5 h for tolbntamide and of 6 h for glibenclamide [23] . The doses of tolbutamide and glibenclamide used in these experiments were comparable to those used in human therapy and were much smaller than those necessary to alter thyroid function and metabolic rate [24] and thus complicate the interpretation of the results.
Results
During the first 30 rain of perifusion, the concentration of insulin in a buffer containing glucose at a concentration of 50 rag/100 ml, fell to a plateau that lasted as long as the medium remained the same. No significant differences were noted between control arrd tolbutamide or insulin treated animals (Fig. 1) . When the medium was exchanged for one containing glucose at a concentration of 300 rag/100 ml, the rate of insulin secretion increased rapidly and 30 to 45 rain later reached a new plateau, where it remained for the duration of the experiment. Under these experimental conditions, insulin secretion was unaffected by previous insulin treatment, but was markedly depressed by treatment with tolbutamide (Fig. 2) . The biphasie response to glucose stimulation was obliterated by the process of averaging, but could he demonstrated in individual experiments. Table 1 shows that insulin treatment did not alter the pattern of insulin secretion of unstimulated islets (glucose concentration 50 rag/ 100 ml of medium) and of islets stimulated with glucose (300 mg/100 ml of medium). Table 1 shows also that treatment with tolbutamide did not decrease significantly the total amount of insulin released by unstimulated islets, but reduced the total amount of 
* NS = Not Significant Table 3 . Tables 2  and 3 . Pancreatic tissue from control animals produced insulin of higher specific activity when stimulated with glucose, while tolbutamide, added to a medium contah~ing small amounts of glucose, had no effect. Treatment with insulin did not alter significantly the specific activity of insulin extracted from the pancreas incubated under basal or under stimulated conditions, the response to glueose was prevented by treatment with glibenelamide and depressed, almost to the level of statistical significance (p < 0.06) by treatment with tolbutamide. Table 3 shows also that when the mice were allowed to survive for 6 days without treatment, the specific activity of insulin was no longer significantly different from that of the pancreatic insulin of the tolerance of rats for intravenous glucose was decreased ( Figs. 3 and 4) and the hypoglyeemic effect of intravenous tolbutamide was abolished (Fig. 5) . Both drugs suppressed the insulinogenic response to intravenous glucose and to intravenous to!butamide (Figs. 6--8). Table 6 shows that the various forms of treatment did not affect the weight of the animals significantly.
Incorporation of leucine-l-laC into an insulin.rich extract of the pancreas of control mice and of mice treated with glibenclamide. Leucine concentration in the medium 1.78 x 10 -8 ~.M/m~, corresponding to 0.5 ~c/ml. Number of animals i n parentheses

Discussion
The release of insulin by isolated perifused pancreatic islets was characterized by a rapid decline to a relatively stable plateau, followed by a secondary rise, when the glucose concentration in the medium was Table 4 shows that the production of laCO~ from glucose-U-14C by isolated islets was greater when the concentration of glucose in the incubation medium was 300 mg/100 ml, than when it was 100 rag/100 ml. This effect of glucose was significantly smaller when the islets were obtained from animals treated with tolbutamide. The metabolic activity of the islets of tolbutamide and of insulin treated animals, incubated in the presence of low glucose concentrations was not significantly different from that of the control islets, although they were different from each other. Table 5 shows that treatment with tolbutamide or with insulin resulted in a comparable, mild degree of fasting hypoglycemia, but did not modify significantly the blood glucose concentration of fed animals. Nevertheless, the serum insulin level was lower in the tolbutamide treated than in the control, fed animals.
After a single injection or after 8 weeks of treatment with glibenelamide, but not with tolbutamide, Hamsters  149  31  148  28  Mature  Hamsters  167  12  153  7  161  10  Mice  28  12  27  4 increased. Although, in individual experiments, this secondary rise was preceded by a small peak, no clear cut biphasic response was obtained. Similar secretory kinetics have been noted also by other investigators using perifused islets [25] . The initial decline and the lack of a distinct first phase in response to glucose stimulation may represent evidence that exposure to collagenase [26] and other manipulations required to prepare the islets for perEusion, may predispose them but also the maximum rate of secretion attained at any time during the experiment, confirming the results obtained in experiments with perfused rat pancreas [4] and with isolated islets [16] . The marked degranulation [27] and the decrease in islet volume [16] We have confirmed the observation that the incorporation of labelled amino acids into insulin is increased by glucose [28] , but not by tolbutamide added in vitro [29--31] . In addition, we have found that following prolonged treatment with sulfonylureas the pancreas, when incubated in a glucose containing medium, produced an insulin of similar or significantly lower specific activity than the pancreas of control animals. Abundant direct [32--35] and indirect [36, 37] evidence demonstrates that pancreatic islets or pancreatic slices metabolize glucose in vitro. Under the conditions of our experiments, the production of t4C02 from labelled glucose by the islets of animals treated with tolbutamide was significantly depressed, although it was not affected by treatment with insulin.
Thus, our experiments indicated that the islets of animals treated with sulfonylureas were functionally depressed, that is, they synthesized and secreted less insulin and oxidized less glucose than the islets of control animals. Six days after cessation of treatment, partial recovery from the sulfonylurea-indueed suppression appeared to have occurred. These results extend those previously reported from our laboratory, indicating that prolonged treatment with tolbutamide decreased the insulin content of the pancreas [16] . Thus, it would appear that at least two sulfonylurea drugs, when administered in amounts proportional to those used in human therapy, tended to suppress three parameters of B cell function (insulin release, insulin synthesis, glucose metabolism) in one or the other of three animal species. This conclusion stands in sharp contrast ~dth that of other investigators [1, 5, 6, 13, 37, 39] who found evidence of islet hyperfunetion after prolonged treatment with sulfonylureas. Differences in animal species, in the intensity and duration of therapy and the use of normal instead of alloxan diabetic animals are possible, albeit unsatisfactory, explanations for this contrast. Perhaps the answer lies in the fact that most of the evidence for a lasting betacytotrophic action of the sulfonylureas was derived from morphologic observations and most of the evidence against it from biochemical and physiologic evidence.
The mechanism by which, in our experiments, the sulfonylureas suppressed islet function remains to be clarified. Four factors may be considered: hypoglycemia, anorexia and malnutrition, elevated serum insulin levels and a direct effect of the drugs on the beta cells. Hypoglycemia and anorexia are not probable explanations because, when fasting hypoglycemia was induced by insulin or by phlorizin [40] , the function of the beta cells was not modified significantly and, above all, because hypoglycemia was not observed when our animals had free access to food, which, judging by the changes in body weight, they consumed in normal amounts [16] . High serum insulin levels could have inhibited islet function [41--45]; however, no significant hyperinsulinism was noted in our sulfonylurea treated animals. Thus, a direct action of the drugs on the beta cells emerges as the most likely cause of these observations. In support of this conclusion, the foliowing evidence may be cited: carbutamide and glibenclamide lower the ATP [46] and the glucose-6-phosphate content of isolated islets [46, 47] , even as glibenclamide and tolbutamide increase their oxygen consumption and laetate production [33, 48] . Thus, although there is some exddenee to the contrary [37, 49] , the sulfonylureas may uncouple oxidative phosphorylation in the islets, as they appear to do in liver, diaphragm and adipose tissue [50, 51] . In so doing, these drugs inhibit the energy producing reactions required for the synthesis of insulin. The decrease in glucose tolerance and in the insulinogenic effect of glucose, observed in animals treated with a single injection of glibenelamide, does not help in the interpretation of the results, for it was due, most likely, to acute insulin depletion. What our results indicate is that this depletion continues as long as the drug is being administered to the animal.
The mechanism whereby the protracted use of sulfonylureas has a lasting effect on the concentration of blood glucose remains unresolved: normal rodents are probably different from diabetic patients in whom hyperglycemia may stimulate the islets directly or alter their response to the drug; nevertheless, we believe that the evidence presented in this paper reinforces the argument that the mechanism may be, in part, extrapancreatic [3, 52, 53] .
